Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2025 | 12-2024 | 09-2024 | 06-2024 | 03-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 725,000 | 414,000 | 2,502,000 | 2,913,000 | 2,329,000 |
| Receivables | 2,693,000 | 2,558,000 | 2,501,000 | 2,400,000 | 2,304,000 |
| Inventories | 2,867,000 | 2,810,000 | 2,753,000 | 2,608,000 | 2,561,000 |
| Other current assets | 756,000 | 831,000 | 673,000 | 755,000 | 672,000 |
| TOTAL | $7,335,000 | $6,920,000 | $8,761,000 | $8,991,000 | $8,185,000 |
| Non-Current Assets | |||||
| PPE Net | 3,389,000 | 3,294,000 | 3,072,000 | 2,951,000 | 2,897,000 |
| Intangibles | 23,906,000 | 23,773,000 | 20,787,000 | 19,814,000 | 20,200,000 |
| Other Non-Current Assets | 5,510,000 | 5,409,000 | 5,458,000 | 5,352,000 | 5,388,000 |
| TOTAL | $32,805,000 | $32,476,000 | $29,317,000 | $28,117,000 | $28,485,000 |
| Total Assets | $40,140,000 | $39,395,000 | $38,078,000 | $37,108,000 | $36,669,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 777,000 | 1,778,000 | 1,652,000 | 1,580,000 | 1,085,000 |
| Accounts payable and accrued liabilities | 1,004,000 | 960,000 | 907,000 | 906,000 | 921,000 |
| Accrued Expenses | 2,354,000 | 2,773,000 | 2,460,000 | 2,320,000 | 2,083,000 |
| Other current liabilities | 923,000 | 887,000 | 891,000 | 770,000 | 827,000 |
| TOTAL | $5,058,000 | $6,399,000 | $5,910,000 | $5,576,000 | $4,916,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 10,532,000 | 8,968,000 | 9,233,000 | 8,991,000 | 9,534,000 |
| Other Non-Current Liabilities | 1,948,000 | 1,875,000 | 1,841,000 | 1,802,000 | 1,920,000 |
| TOTAL | $12,636,000 | $10,993,000 | $11,212,000 | $10,923,000 | $11,585,000 |
| Total Liabilities | $17,694,000 | $17,392,000 | $17,122,000 | $16,499,000 | $16,501,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,479,446 | 1,475,778 | 1,473,827 | 1,472,626 | 1,470,180 |
| Common Shares | 17,000 | 17,000 | 17,000 | 17,000 | 17,000 |
| Retained earnings | 3,347,000 | 2,673,000 | 2,107,000 | 1,639,000 | 1,314,000 |
| Other shareholders' equity | 206,000 | 508,000 | 120,000 | 401,000 | 375,000 |
| TOTAL | $22,446,000 | $22,003,000 | $20,956,000 | $20,609,000 | $20,168,000 |
| Total Liabilities And Equity | $40,140,000 | $39,395,000 | $38,078,000 | $37,108,000 | $36,669,000 |